Korea Building stronger bridges between Korean biotech companies and global capital will be critical to unlocking the ecosystem’s full potential Chang Woo Lee, CEO of CUROGEN, discusses translating academic science into innovative medicines, developing multispecific proteins and an oral IBD therapy, and pursuing global expansion. He highlights Korea’s biotech strengths and…
Germany What begins as frustration with the limits of academic research has developed into a story of entrepreneurship, scientific translation and sustainable biotech growth. Dr Thomas Schirrmann, Co-Founder and CEO of YUMAB, reflects on building a therapeutic antibody specialist from Braunschweig without conventional venture capital, competing through scientific expertise and flexibility,…
Germany We want to provide all patients – privately or publicly insured – with rapid access to innovative therapies Germany’s statutory health insurers are under growing pressure to control pharmaceutical spending without compromising patient access to innovative therapies. As one of the country’s largest purchasing associations, GWQ ServicePlus AG pools the…
Korea What I want, more than anything, is to introduce this modality to patients as quickly and as properly as possible Jaejin Cho, CEO of CellinCells, explains how the company’s proprietary Tissue Reforming Technology Platform (TRTP) translates developmental biology and quantitative tissue design into scaffold-free therapeutic tissue modules. He discusses the…
Hong Kong After a rocky couple of years, Hong Kong has defied its sceptics and definitively bounced back. As Asia’s financial capital and the bridge between mainland China and international markets, the global stock market slump between 2021 and 2024 had an outsized impact on Hong Kong, with sluggish GDP growth and…
Hong Kong Hong Kong’s biotech capital market has completed one of the more dramatic reversals in recent years. After a brutal two-year drought in which valuations collapsed, liquidity evaporated, and companies were forced to sell assets just to survive, the market roared back in 2025 – reclaiming the top global position for…
Hong Kong Hong Kong’s capital markets are entering a more dynamic phase, underpinned by a gradual return of international investors, a maturing innovation ecosystem, and targeted reforms aimed at improving market access and efficiency. As Johnson Chui explains, the growing momentum across healthcare, biotech, and technology is reinforcing Hong Kong’s role not…
China China Biotech private financing in H2 2025 reflected a distinct “flight to quality,” moving from the valuation outliers of Q3 toward a disciplined clinical focus in Q4. As Dr Cathy Bi of PharmaBoardroom content partner Selesta writes, while early-stage deal volume cooled, strategic liquidity remained robust for assets with mature…
Taiwan Lih-Chung Chien, Chairman of the Taipei Exchange (TPEx), highlights the Exchange’s support for SMEs and innovative sectors via a three-tiered market, flexible IPO rules, and the Technology-Based Enterprise mechanism. Taiwan’s strong clusters in biotech, ICT, and semiconductors, along with supportive policies and active investor participation, make it a compelling destination…
Taiwan Built around an engineering mindset and a clear view of where a smaller biotech can compete, Pharmosa is pursuing a differentiated path in pulmonary hypertension and related rare diseases through drug-device combination therapies. In this discussion, Pei Kan outlines how scientific focus, selective partnerships, disciplined capital allocation, and early investment…
USA Cardiff Advisory’s David H. Crean outlines how the 2026 JP Morgan Healthcare Conference signaled a shift from sector reset to disciplined re-acceleration in global biopharma. Dr Crean explores investor sentiment, capital markets dynamics, M&A and venture activity, and the strategic priorities shaping 2026, highlighting why execution, selectivity, and capital discipline…
Taiwan Dr Shuling Cheng is steering Oneness Biotech through a pivotal transition from a Taiwan-based research organisation to a globally focused commercial company. After 25 years in US biotech and medtech, she returned to Taiwan a decade ago and brought two companies to IPO on the Taipei stock exchange. She joined…
See our Cookie Privacy Policy Here
